Takeda Put Actos Profits Before Patient Safety, Jury Told

Law360, Los Angeles (April 15, 2013, 9:55 PM EDT) -- Japan's Takeda Pharmaceutical Co. put profits from its diabetes drug Actos ahead of patient safety in failing to adequately disclose the drug's link to bladder cancer, an attorney for a man dying of the disease said Monday during closing arguments in the first product liability trial of its kind.

Michael Miller said diabetes drugs are “big business” in America and Takeda delayed adding a bladder cancer warning to the Actos product label for at least five years so it could continue making billions of dollars a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.